Shares of Lupin Ltd were trading in the green and 2% higher on 12 November after the subsidiary of the company commissioned an Oncology block. 

In its regulatory filing, the company said that its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), commissioned a dedicated Oncology Block at its Vizag facility in India. 
 
The new high-containment unit majorly boosts LMS’s Contract Development and Manufacturing (CDMO) capabilities for High Potent Active Pharmaceutical Ingredients (HPAPIs), catering to the rising global demand in oncology drug development.

The facility spans 4,270 square meters and includes 20 reactors (250L-2000L) and over 20 isolators. Advanced containment technologies provide exposure levels of ≤0.05 µg/m³. It enables variable scale-up (1-35 kg batches) and strict environmental conditions (≤25°C, ≤45% RH) for safe and compliant API production that meets global quality requirements.

The Oncology Block combines a Process Development Laboratory and a Quality Control Laboratory under one roof, allowing for route discovery, analytical development, process optimisation, and validation.  It is run by scientists with HPAPI knowledge, ensuring a smooth transition from lab-scale to commercial manufacture.

The facility meets global regulatory and environmental safety standards by utilising isolator-based operations, integrated SCADA systems, and a strong effluent purification process.  

With this expansion, LMS solidifies its position as a reliable worldwide CDMO partner by combining Lupin’s scientific expertise with cutting-edge containment and regulatory skills to accelerate oncology medication development from concept to commercialisation.

Lupin Limited, based in Mumbai, is a significant global pharmaceutical firm with a presence in over 100 markets. The company creates and manufactures a wide range of branded and generic formulations, complicated generics, biotechnology products, and active pharmaceutical ingredients (APIs).  

Lupin, which has a major presence in India and the United States, specialises in respiratory, cardiovascular, diabetic, infectious diseases, gastrointestinal, central nervous system, and women’s health treatments.

Lupin, with 15 advanced manufacturing facilities, 7 research centres, and a workforce of over 24,000 people, is committed to improving patient health outcomes through its subsidiaries, Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

At 3:08 pm, the shares of Lupin were trading 2.87% higher at Rs 2,032.60 on NSE.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!